| Business Summary | | Bio-Technology
General
Corp.
is
engaged
in
the
research,
development,
manufacture
and
marketing
of
biopharmaceutical
products.
The
Company
has
developed
a
portfolio
of
therapeutic
products,
including
eight
products
that
have
received
regulatory
approval
for
sale,
of
which
seven
are
currently
being
marketed.
Additionally,
the
Company
has
four
products
in
registration
or
clinical
trials
and
several
products
in
pre-clinical
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BTGC
is
engaged
in
the
research,
development,
manufacture
and
marketing
of
biopharmaceutical
products
through
a
combination
of
R&D,
acquisition,
collaboration
and
licensing
agreement.
For
the
six
months
ended
6/30/01,
revenues
rose
49%
to
$61.9
million.
Net
loss
before
accounting
change
totaled
$29.1
million,
vs.
an
income
of
$6.7
million.
Results
reflect
increased
sales
of
Oxandrin,
offset
by
a
$45.6
million
charge
for
the
write-off
of
purchased
technologies. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Sim Fass, Ph.D., 59 Chairman,
CEO, Treasurer | $555K | -- | John Bond Sr.
VP-Fin. | -- | -- | Robert Shaw, 47 Sr.
VP, Gen. Counsel, Sec. | 296K | $60K | Norman Barton, M.D., Ph.D., 53 CMO
and Sr. VP | 292K | 720K | Dov Kanner, Ph.D., 47 Sr.
VP; Gen. Mang., BTG-Israel | 320K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|